Document Detail


Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
MedLine Citation:
PMID:  19673889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ATP-binding cassette (ABC) transporters (ABC-T) actively efflux structurally and mechanistically unrelated anticancer drugs from cells. As a consequence, they can confer multidrug resistance (MDR) to cancer cells. ABC-T are also reported to be phenotypic markers and functional regulators of cancer stem/initiating cells (CSC) and believed to be associated with tumor initiation, progression, and relapse. Dofequidar fumarate, an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both. Phase III clinical trials suggested that dofequidar had efficacy in patients who had not received prior therapy. Here we show that dofequidar inhibits the efflux of chemotherapeutic drugs and increases the sensitivity to anticancer drugs in CSC-like side population (SP) cells isolated from various cancer cell lines. Dofequidar treatment greatly reduced the cell number in the SP fraction. Estimation of ABC-T expression revealed that ABCG2/breast cancer resistance protein (BCRP) mRNA level, but not the ABCB1/P-gp or ABCC1/MDR-associated protein 1 mRNA level, in all the tested SP cells was higher than that in non-SP cells. The in vitro vesicle transporter assay clarified that dofequidar had the ability to suppress ABCG2/BCRP function. Dofequidar treatment sensitized SP cells to anticancer agents in vitro. We compared the antitumor efficacy of irinotecan (CPT-11) alone with that of CPT-11 plus dofequidar in xenografted SP cells. Although xenografted SP tumors showed resistance to CPT-11, treatment with CPT-11 plus dofequidar greatly reduced the SP-derived tumor growth in vivo. Our results suggest the possibility of selective eradication of CSC by inhibiting ABCG2/BCRP.
Authors:
Ryohei Katayama; Sumie Koike; Shigeo Sato; Yoshikazu Sugimoto; Takashi Tsuruo; Naoya Fujita
Related Documents :
8337699 - Modification of mipafox-induced inhibition of neuropathy target esterase in neuroblasto...
20621639 - Differences in assessment of macrolide interaction with human mdr1 (abcb1, p-gp) using ...
19472369 - Cells need safety valves.
10850629 - Establishment and characterization of renal cell carcinoma cell lines with multidrug re...
15256459 - Efflux kinetics and intracellular distribution of daunorubicin are not affected by majo...
15848949 - Antibiotic exposure does not influence mrp2 functional expression in caco-2 cells.
7672449 - The location and the regulation of the type i-iodothyronine 5'-monodeiodinase (type i-m...
6973569 - Human bone cells in culture metabolize 25-hydroxyvitamin d3 to 1,25-dihydroxyvitamin d3...
15234079 - Genotoxicity and mutagenicity of melanoidins isolated from a roasted glucose-glycine mo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-07-17
Journal Detail:
Title:  Cancer science     Volume:  100     ISSN:  1349-7006     ISO Abbreviation:  Cancer Sci.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-20     Completed Date:  2009-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101168776     Medline TA:  Cancer Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  2060-8     Citation Subset:  IM    
Affiliation:
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Japanese Foundation for Cancer Research, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ATP-Binding Cassette Transporters / antagonists & inhibitors*,  physiology
Animals
Antineoplastic Agents / pharmacology*
Camptothecin / analogs & derivatives,  pharmacology
Cell Line, Tumor
Female
Humans
Methotrexate / pharmacokinetics
Mice
Mice, Inbred BALB C
Neoplasm Proteins / antagonists & inhibitors*,  physiology
Neoplastic Stem Cells / drug effects*
Quinolines / pharmacology*
Chemical
Reg. No./Substance:
0/ABCG2 protein, human; 0/ATP-Binding Cassette Transporters; 0/Antineoplastic Agents; 0/Neoplasm Proteins; 0/Quinolines; 100286-90-6/irinotecan; 158681-49-3/dofequidar; 59-05-2/Methotrexate; 7689-03-4/Camptothecin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.
Next Document:  Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD...